Congress Materials – International Prostate Cancer Update (IPCU 2026)
2026 International Prostate Cancer Update | Feb 1-4 | Vail, CO
This section includes selected Johnson & Johnson Innovative Medicine abstracts, posters, or oral presentations, which have been accepted for congress presentations in the last 2 years or less (as determined by any congress restrictions on length of time materials can be posted). Information about pipeline products or investigational uses of products does not imply FDA approval for these products or uses, nor does it establish the safety or efficacy of these products or uses. Johnson & Johnson does not recommend or suggest use of its medicines in a manner inconsistent with FDA-approved labeling. The content contained in this section is subject to congress copyright permissions.
A real-world comparison of deep prostate-specific antigen response in patients with metastatic castration-sensitive prostate cancer initiated on apalutamide or abiraterone acetate
Gordon Brown, Benjamin Lowentritt, Mukul Singhal, Frederic Kinkead, Dominic Pilon, Courtney D. Morrow, Mehmet A. Bilen
Comparison of early and deep prostate-specific antigen response in real-world patients with metastatic castration-sensitive prostate cancer treated with apalutamide or enzalutamide
Mehmet A. Bilen, Gordon Brown, Mukul Singhal, Carmine Rossi, Dominic Pilon, Courtney D. Morrow, Benjamin Lowentritt
Real-world comparison of overall survival in patients with metastatic castration-sensitive prostate cancer initiating apalutamide without docetaxel versus darolutamide without docetaxel
Benjamin Lowentritt, Mehmet A. Bilen, Mukul Singhal, Carmine Rossi, Dominic Pilon, Courtney D. Morrow, Gordon Brown
Copies of these presentations are for personal use only and may not be reproduced without written permission from the presentation author.